Close this search box.

PrecorDx Wins the Venture Challenge Fall 2022!

The winner of the Venture Challenge was announced today at the Dutch Life Sciences Conference. The proud winner of the 2022 fall edition is PrecorDx! The innovative startup PrecorDx has developed a non-invasive diagnostic platform aimed at reducing hospitalization & slowing disease progression in heart failure.</strong>

According to the jury, composed of Carine van den Brink, Rob de Ree, Brigitte Drees, Ivan Burkov and Sterre Witteveen, PrecorDx is addressing a real need as experienced by patients suffering from heart failure. They have a clear value proposition on which they can expand in the future. Several studies show that hospitalization can be significantly reduced  and disease progression slowed in heart failure patients by monitoring disease progression and adapting medication accordingly. This is currently only possible with an invasive device (CardioMems, Abbott). PrecorDx offers a non-invasive solution to monitor heart failure disease progression. This new diagnostic modality is based on the unique, novel Radio-Frequency Sensing (RFS) technology, which was invented in by Bart Steensma and Nico van den Berg, researchers from the computational imaging group at the UMC Utrecht and patented in 2021. Because of the existing clinical evidence, PrecorDx expects an accelerated time to market by comparing the diagnostic value of RFS directly with its invasive competitor. The PrecorDx team currently consists of Bart Steensma, Nico van den Berg and Jaap de Bruin representing a mix of academic/technical expertise and business expertise. The team has built a strong network of clinical advisors which have confirmed the value proposition for heart failure monitoring. Finally, various follow-on applications have been identified, with total market opportunity potential exceeding >€500M.

‘The Venture Challenge was an incredibly effective experience to accelerate & sharpen our business plan. With PrecorDx, we are on a mission to realize a new diagnostic modality in cardiology. We are very excited to set the next steps in the development of the RF Sensing technology!’

– Jaap de Bruin, co-founder of PrecorDx

The Venture Challenge Fall started in September and today at the Dutch Life Sciences Conference 2022 PrecorDx takes home the €25.000 prize money to invest in their growth. The other highly-motivated participating teams were: BeephonixNatInLabD4 Diagnostics and Movax. Contact Jaap de Bruin for more information about PrecorDx.

PrecorDx team with cheque
© Nils van Houts Fotografie

Participating in the Venture Challenge leads to a clear venture plan, as well as to investor-ready pitches. The  Venture Challenge  is an instrument of the ministry of Economic Affairs and Climate Policy, powered by  Health~Holland, Top Sector Life Sciences & Health and organized in collaboration with NWO.

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?


The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.